Acadia's prized pain drug from $52M buyout flops its first test

Amber Tong

Senior Editor

When Acadia Pharmaceuticals put down $52.5 million in cash to buy out CerSci Therapeutics – along with $887 million in biobucks – in 2020, CEO Steve Davis made clear that its non-opioid painkillers for acute and chronic pain, particularly the lead compound, ACP-044, was the star of the show. A Phase II study was being planned for the following year.

The results are now in. And they don’t bode well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Acadia's prized pain drug from $52M buyout flops its first test

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Ono Pharmaceutical acquires Deciphera for $2.4B after biotech's Phase 3 win

Bristol Myers buys into Repertoire's autoimmune vaccines, giving new life to Flagship startup

FDA approves X4 Pharmaceuticals' pill for ultra-rare immunodeficiency disease

AstraZeneca, Daiichi Sankyo’s Enhertu claims another Phase 3 victory in HER2-low breast cancer

Lead drug from J&J and Addex's 20-year collaboration flunks Phase 2 in epilepsy

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Aca­di­a's prized pain drug from $52M buy­out flops its first test

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Ono Phar­ma­ceu­ti­cal ac­quires De­ci­phera for $2.4B af­ter biotech's Phase 3 win

Bris­tol My­ers buys in­to Reper­toire's au­toim­mune vac­cines, giv­ing new life to Flag­ship start­up

FDA ap­proves X4 Phar­ma­ceu­ti­cal­s' pill for ul­tra-rare im­mun­od­e­fi­cien­cy dis­ease

As­traZeneca, Dai­ichi Sankyo’s En­her­tu claims an­oth­er Phase 3 vic­to­ry in HER2-low breast can­cer

Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

Acadia's prized pain drug from $52M buyout flops its first test

Ono Pharmaceutical acquires Deciphera for $2.4B after biotech's Phase 3 win

Bristol Myers buys into Repertoire's autoimmune vaccines, giving new life to Flagship startup

FDA approves X4 Pharmaceuticals' pill for ultra-rare immunodeficiency disease

AstraZeneca, Daiichi Sankyo’s Enhertu claims another Phase 3 victory in HER2-low breast cancer

Lead drug from J&J and Addex's 20-year collaboration flunks Phase 2 in epilepsy

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations